Clinical trials: Nutrition Disorders
Diabetes Mellitus, Type 2, Obesity
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.
- Trial name
- NCT07172867
- Testing
- HT-6184, Semaglutide 1 mg
- Where
- United Arab Emirates
- Sponsor
- Halia Therapeutics, Inc.
Overweight, Obesity
Weight Loss Using the Take Shape For Life Program or the Medifast Direct Program Versus a Self-Directed Diet
The study evaluates the effects of two commercially available weight loss programs, the TSFL and the MEDD programs, each compared to a self-directed control diet, on changes in body weight over a 16-week weight loss phase, in…
- Trial name
- NCT02835092
- Testing
- Take Shape For Life Program, Medifast Direct Program, Self-directed Control
- Where
- United States
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Medifast, Inc.
Cholesterol Lowering
Influence of Polyglucosamine L112 on Serum Surrogate Markers of Cholesterol Absorption
Obesity is widespread and the number of overweight people has tripled from 1975 to 2016. According to the WHO (World Health Organisation), 1.9 billion adults worldwide are overweight, of which 650 million are obese.
- Trial name
- NCT05038436
- Testing
- Polyglucosamine L112
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
Overweight, Obesity
A Study Collecting Remote Data in People With an Overweight Condition or Obesity on a Weight Management Program
The purpose of this study is to collect health data related from participants living with an overweight condition in a decentralised clinical study set-up.
- Trial name
- NCT06805539
- Testing
- No treatment given
- Where
- Denmark
- Volunteers
- 146 people
- Sponsor
- Novo Nordisk A/S
Psychological Phenomena and Processes, Nutrition Physiological Phenomena
The Effects of Fiber on Appetite and Digestion Hormones
In this research study, investigators are interested in how certain dietary fibers in the diet affect certain hormones released from your intestine after eating and how these influence your appetite.
- Trial name
- FS (NCT01050101)
- Testing
- No fiber, Low GI high fiber viscous meal, Low GI high fiber non-viscous
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Vitamin D Deficiency
Evaluation Of The Effect Of L. Casei DG® On Vitamin D Absorption In Patients Under Vitamin D Supplementation.
Vitamin D deficiency is one of the most underdiagnosed and undertreated medical condition worldwide . The microbiome and vitamin D deeply influence each other and the immune system in many different ways.
- Trial name
- NCT05394207
- Testing
- L. casei DG® (Lactobacillus paracasei CNCM I-1572)
- Where
- United Arab Emirates
- Volunteers
- 46 people
- Sponsor
- SOFAR S.p.A.
Type 2 Diabetes Mellitus
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open study of PF-07081532.
- Trial name
- NCT05158244
- Testing
- PF-07081532
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Pfizer
Obesity
Safety and Efficacy of Low Doses of V24343 in Obese Subjects
Randomised, double-blind, parallel group comparison of four dose levels of V24343 and placebo to study the effect of V24343 on blood pressure and weight in obese subjects.
- Trial name
- NCT00734201
- Testing
- V24343
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vernalis (R&D) Ltd
Overweight or Obesity
Multicenter Trial Investigating Performance and Safety of the Medical Device SiPore21®
The present clinical investigation is a randomized, double-blinded, placebo-controlled, multicenter international trial, planned to be conducted in Poland, Romania and Slovakia.
- Trial name
- SHINE (NCT06087822)
- Testing
- IMD SiPore21®
- Where
- 27 sites in Poland, Romania and 1 more
- Volunteers
- 318 people
- Sponsor
- Sigrid Therapeutics AB
Diabetes Mellitus, Type 2, Insulin Resistance
Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes
This study will investigate the safety and efficacy of the investigational use of the HydraSolve T2D™ System in improving blood glucose control and insulin resistance in patients with obesity (Class 1, BMI 30-39.9 kg/m2) and type…
- Trial name
- NCT03953963
- Testing
- HydraSolve T2D™
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medality Medical
Abdominal Obesity, Type 2 Diabetes
ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT
Weight control is an essential part of treatment for type 2 diabetes (T2D) patients. Weight loss is associated with decreased haemoglobin A1c (A1c) levels.
- Trial name
- NCT05032001
- Testing
- Biguanide, DPP4 inhibitors, SGLT2 inhibitors
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Metabolic Research Unit
Obesity, Healthy Volunteers
Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants
The primary purpose of this study is to determine the effect of repeated administration of itraconazole on the pharmacokinetic (PK) profile of S-309309; and the PK of S-309309 following administration of S-309309 alone and…
- Trial name
- NCT06106334
- Testing
- S309309, Itraconazole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Shionogi
Obesity
LapBand Adjustment to Improve Early Weight Loss
Subjects having a gastric band fitted will have the first band adjustment done at surgery. The stoma will be set to 7mm using the EndoFLIP system to measure stoma size.
- Trial name
- NCT01060592
- Testing
- EndoFLIP device (FDA Device Listing Number : D091203)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Crospon
Overweight, Type 2 Diabetes
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
- Conditions
- Overweight, Type 2 Diabetes, Obesity
- Trial name
- NCT06926842
- Testing
- Petrelintide
- Where
- 48 sites in United States
- Volunteers
- 221 people
- Sponsor
- Zealand Pharma
Obesity
An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED)
A 1 year worldwide study in obese and overweight patients to assess the safety and effect on body weight of an investigational weight loss drug.
- Trial name
- NCT00384605
- Testing
- taranabant
- Volunteers
- 1,000 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy, Obese
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese…
- Conditions
- Healthy, Obese, Overweight, Obesity
- Trial name
- NCT06440980
- Testing
- Orforglipron
- Where
- 7 sites in United States
- Volunteers
- 533 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
Safety and Performance of the CAVU Medical, Inc. Attune Tubing Study
The objectives of this clinical research project are to demonstrate the safety and feasibility of CAVU Medical, Inc.'s Attune Device.
- Trial name
- NCT01422941
- Testing
- CAVU Attune Device
- Where
- 2 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Cavu Medical, Inc.
Obesity
Phase 2a Randomized, Double-Blind Study of Oleoyl-Estrone in Male Morbidly Obese Adults
Multi-center, multiple-dose, randomized, double-blind, three-arm, placebo-controlled study of fixed-dose repeated oral dosing for 30 days of 10 mg and 30 mg MP-101 and placebo in obese subjects.
- Trial name
- NCT00449254
- Testing
- oleoyl-estrone (MP-101)
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Manhattan Pharmaceuticals
Obesity, Overweight
A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity
This study is a randomized, double-blind, placebo-controlled, parallel phase 2 study to evaluate efficacy, safety, pharmacokinetic characteristics and immunogenicity of TG103 injection for weight management in non-diabetic…
- Trial name
- NCT06226090
- Testing
- TG103 7.5 mg, TG103 15 mg, TG103 22.5 mg
- Where
- China
- Volunteers
- 314 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Obesity
A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus
- Trial name
- NCT06174779
- Testing
- HM11260C
- Where
- South Korea
- Volunteers
- 448 people
- Sponsor
- Hanmi Pharmaceutical Company Limited